ArticleiLIVER2025
Integrated multi-omics analysis identifies TPX2 as a potential prognostic and immunological biomarker in hepatocellular carcinoma.
Article in iLIVER, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Prognostic Risk Model for Hepatocellular Carcinoma Integrating Ferroptosis and Metabolic Reprogramming Signatures.Journal of Cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, characterized by aggressive behavior, limited therapeutic efficacy, and poor patient outcomes. TPX2, a microtubule-associated protein essential for mitotic spindle formation, has been associated with tumorigenesis in various cancers. However, its functional significance in shaping the immune landscape and influencing treatment sensitivity in HCC remains insufficiently elucidated. Methods: We conducted an integrated multi-omics analysis using transcriptomic (TCGA, GTEx, GEO), proteomic (CPTAC), and pharmacogenomic (GDSC, PRISM, CTRP) datasets to assess TPX2 expression patterns in HCC. We performed differential expression analysis, survival analysis, Cox regression, and nomogram construction. Co-expression modules were identified via weighted gene co-expression network analysis (WGCNA), followed by GO and KEGG enrichment analyses. The correlations between TPX2 expression levels and immune and genomic features were examined, and drug sensitivity associations were evaluated. Results: TPX2 was consistently overexpressed in HCC tissues and associated with advanced tumor stage, higher grade, and poor survival. WGCNA revealed TPX2-enriched modules linked to cell cycle and DNA replication pathways. High TPX2 expression levels were correlated with immunosuppressive features, including reduced lymphocyte infiltration, lower IFN-γ response, and increased expression levels of immune checkpoint molecules (PD-1, CTLA-4, HAVCR2). TPX2-high tumors also exhibited greater genomic instability. Drug sensitivity analysis indicated resistance to several chemotherapeutics, but increased sensitivity to mitotic inhibitors and targeted agents. Conclusions: TPX2 is a key driver of proliferation and immune evasion in HCC, potentially serving as a diagnostic and prognostic biomarker to guide treatment strategies involving mitotic- or immune-based therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.